¿Es importante la expresión de PDL1 a la hora de considerar el tratamiento del CECC?
|
Número de diapositiva 1 |
1 |
|
Standard of care in R/M disease |
2 |
|
Phase III: Nivolumab vs Monotherapy vs Pembrolizumab |
3 |
|
Número de diapositiva 4 |
4 |
|
Número de diapositiva 5 |
5 |
|
Número de diapositiva 6 |
6 |
|
Overall Response by Tumor PD-L1 Expression and PD-L1+ TAIC Abundance |
7 |
|
Overall Survival by Tumor PD-L1 Expression and PD-L1+ TAIC Abundance |
8 |
|
Overall Survival by Tumor PD-L1 Expression and PD-L1+ TAIC Location |
9 |
|
KEYNOTE-012 |
10 |
|
Tumor and inflammatory cells PD-L1 – Dako 22C3 – Tumor cells PD-L1 |
11 |
|
SCCHN Tumor Response Overall and by PD-L1 StatusDurvalumab Phase I |
12 |
|
Best % change from baseline in tumour size* |
13 |
|
Other biomarkers (KEYNOTE-012) |
14 |
|
Combined biomarkers (KEYNOTE-012) |
15 |
|
Results: long-term survivors versus fast progressors |
16 |
|
Conclusiones |
17 |
|
Número de diapositiva 18 |
18 |